Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universitat Bielefeld currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is focused on a single front, with the active matter assigned to 1 distinct examiner and 1 distinct art unit. This reflects a specific technical focus for the university's current biotechnology research being patented at the USPTO. Practitioners should recognize that this centralized approach allows for a dedicated focus on the specific requirements of the pending application.
The busiest examiner for the university is BRAUN, MADELINE E, who is managing 1 pending office action. Since there is 1 distinct examiner involved in the portfolio, the university's prosecution efforts are concentrated on this individual's assessment. This streamlined engagement in the Biotechnology & Pharmaceuticals sector allows for a focused response to the lone pending office action. The 1 distinct art unit involved indicates that the university's current legal efforts are not fragmented across different technical divisions. This structure facilitates a more direct engagement with the USPTO during the examination process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 1624 | §102§103§112 | Non-Final OA | 5d | Pending | Aug 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversitat Bielefeld has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Madeline E Braun has the most, with 1 of Universitat Bielefeld's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
